Post-Hoc Analysis Confirms Consistent Clinical Benefit With Olaparib Plus Abiraterone in HRR-Mutated mCRPC

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

Related Keywords

Boston ,Massachusetts ,United States ,Bristol Myers Squibb ,Bristol Myers Squibb Sanofi ,Medivation Astellas ,Immunitybio Incyte ,Merck Serono ,Nonagen Bioscience ,Astellas Pharma ,Jiangsu Yahong Meditech ,Pfizer ,Telix Pharmaceuticals ,Carolina Urologic Research Center ,Asieris Pharmaceuticals ,Foundation Medicine ,Clarity Pharmaceuticals ,Astrazeneca ,Amgen ,Aragon Pharmaceuticals ,Speciality Networks ,Myovant Sciences ,Genentech ,Palette Life Sciences ,Guardant Health ,Bureau For Astellas Pharma ,Platformq Health ,Boston Scientific ,Janssen Scientific Affairs ,Cmt Group ,Novartis ,Neal Shore ,Genesiscare United States ,Alessa Therapeutics ,Arquer Diagnostics ,Clovis Oncology ,Exact Imaging ,Exact Sciences ,Fize Medical ,Genesis Cancer Care ,Lantheus Medical Imaging ,Myriad Genetics ,Pacific Edge Biotechnology ,Profound Medical ,Propella Therapeutics ,Protara Therapeutics ,Sesen Bio ,Vessi Medical ,Istari Oncology ,Steba Biotech ,Genitourinary Cancers Symposium Asco Gu ,News ,Prostate Cancer ,Conference ,